Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cue Biopharma, Inc.

Get SEC filing alerts via email and in your feed for Cue Biopharma, Inc.

CUE

Cue Biopharma, Inc.

About Cue Biopharma, Inc.

Cue Biopharma, Inc. develops precision immunotherapies targeting T cells to treat cancer and autoimmune diseases. Its proprietary Immuno-STAT platform selectively modulates disease-relevant T cells, aiming to restore immune balance. The company’s core programs include autoimmune, autoimmune cell depletion, and oncology candidates, with a focus on personalized, targeted biologics designed to improve efficacy and safety over traditional therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cue Biopharma, Inc.

1
1
Cue Biopharma, Inc. Cue Biopharma Reports Increased Collaboration Revenue and Reduced Losses in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Cue Biopharma, Inc. Cue Biopharma Reports Fiscal Year 2025 Financial Results and Business Update

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cue Biopharma, Inc. Cue Biopharma Reports Q3 2025 Financial Results, Collaboration Revenue Declines

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cue Biopharma, Inc. Cue Biopharma Reports Q2 2025 Financial Results, Collaboration Revenue Increases 11%

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cue Biopharma, Inc. Cue Biopharma Reports Q1 2025 Financial Results, Collaboration Revenue Declines

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cue Biopharma, Inc. Cue Biopharma Reports $40.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cue Biopharma, Inc. Cue Biopharma Reports Q3 2024 Financial Results, Revenue Growth and Reduced Net Losses Amid Ongoing Cash Flow Concerns

Via official filing (AI summary) | over 1 year ago | 0 comments